Practical biomarkers of Alzheimer disease

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43ES022892-01
Agency Tracking Number: R43ES022892
Amount: $199,921.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solicitation Year: 2012
Solicitation Topic Code: NIEHS
Solicitation Number: OD12-003
Small Business Information
BOX 520, 7420 92ND PL SE, MERCER ISLAND, WA, 98040-5808
DUNS: 827160974
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 (206) 230-5581
Business Contact
Phone: (206) 999-9086
Research Institution
DESCRIPTION (provided by applicant): Alzheimer's disease (AD), the most common geriatric dementia, has become a major threat to aging baby boomers and presents one of the leading, long-term economic and health burdens to our society. The estimated cost ofAD in the US for health care and hospice in the long run is projected to exceed 183 billion in 2011 and to reach over 1.1 trillion by 2050. The cumulative costs of care will break 20 trillion over the next 40 years. The major challenge AD presents todayis that the disease cannot be diagnosed clinically, with confidence, until a majority of neurons have already degenerated in several key brain regions--including the hippocampus which is critical to memory functions. Thus, there is an urgent need to develop biomarkers that can detect AD at its earliest stages. Several promising biomarkers have been revealed to assist AD diagnosis at symptomatic stages as well as in an early phase of AD, mild cognitive impairment; however, all of these markers are either neuroimaging-based, which is quite expensive and has limited accessibility, or cerebrospinal fluid (CSF)-based, which carries relative risk to the patients when the samples are obtained by lumbar puncture. Lumbar puncture is also technically difficult to perform in routine clinical practices. Motivated by our recent discovery that tau species (proteins intimately involved in AD pathogenesis but not detectable in blood) presents itself in human saliva, with changes unique to AD, in this application we proposeto develop practical assays using easily accessible saliva for AD diagnosis and progression or assessment of existing and future therapeutics. Salivary biomarkers, if confirmed in this SBIR Phase I application, can also be potentially used as a screening assay in the general population in a Phase II SBIR. The current investigations will be focused on tau and A species (another key component of AD pathology) with the goal of developing robust biomarkers that can be adapted swiftly to daily clinical practice, even in remote areas of developed countries or in developing countries. PUBLIC HEALTH RELEVANCE: Developing a user-friendly diagnostic tool using an easily accessible body fluid like saliva will greatly enhance the chance of diagnosing Alzheimer's disease in its early stages, thereby expanding the therapeutic window.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government